TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02. Comparison with reference inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling. TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60). These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clinical evaluation of TG02 in patients with advanced leukemias.
Introduction
Kinase inhibitors have found increasing use in clinical oncology as molecularly targeted therapeutics, due largely to advances in our understanding of the pivotal signaling pathways that trigger and sustain the malignant state. 1 In many cases, broad-spectrum inhibitors have yielded superior efficacy compared with traditional agents, as exemplified by multi-kinase inhibitors such as sunitinib 2 and sorafenib. 3 The utility of these drugs is often a consequence of the simultaneous targeting of multiple pathways critical for tumor growth, including those contributing to proliferation, angiogenesis and apoptotic regulation.
Among the best characterized pathways in relation to cellular proliferation are those under the control of cyclin-dependent kinases (CDKs). CDKs are serine-threonine kinases that have important roles in cell cycle control (CDK1, 2, 4 and 6), initiation of transcription (CDK7 and 9), and neuronal development (CDK5). 4 Aberrations in the cell cycle CDKs and their cyclin partners have been observed in various tumors, including those of the breast, colon, liver and brain. 5 It is believed that pharmacological inhibition of some of these kinases may provide new therapeutic options for cancer patients. In particular, the simultaneous inhibition of CDK1, 2 and 9 has recently been shown to increase apoptotic killing of lung cancer and osteosarcoma cells compared with the inhibition of a single CDK alone. 6 The Janus Kinase (JAK) family consists of four protein tyrosine kinases that have important roles in the cellular signaling pathways, controlling proliferation, differentiation and apoptosis. 7 Among them, JAK2 has a prominent role in mediating many aspects of hematopoiesis from stem cells to the myriad of specialized blood cells. Consequently, genetic aberrations involving JAK2 have been found to be associated with a wide spectrum of hematological malignancies, including myeloproliferative neoplasms, lymphomas and some rare leukemias. 8 FLT3 (fms-like tyrosine kinase-3) belongs to a family of Class III receptor tyrosine kinases and is the most frequently mutated gene in acute myeloid leukemia (AML) associated with poor prognosis in patients. 9 As myeloproliferative neoplasms and AML continue to present as unmet medical needs in hematology, JAK2 and FLT3 offer hope as novel targets for the development of innovative therapies.
Macrocyclic natural products possess conformationally defined ring structures that have evolved to interact with proteins and influence their function. 10 Synthetic macrocyclic organic compounds offer great potential for pharmacological applications, but synthetic challenges and poor pharmacologic properties have limited their application. Recent advances in synthetic medicinal chemistry are beginning to change this scenario. 10 In this study, we report the pharmacological profile of TG02, a novel, low molecular-weight synthetic macrocycle with potent inhibitory activities against several CDKs, JAK2 and FLT3. TG02 exhibits favorable physico-chemical and pharmaceutical properties and demonstrates efficacy in in vitro and in vivo models of hematological malignancies as well as primary cells from patients with erythroid and myeloid malignancies. Findings from these studies provide the rationale for the ongoing clinical evaluation of TG02 in patients with advanced hematological malignancies.
Materials and methods

Compounds and reagents
TG02, originally designated SB1317, was discovered by S*BIO (Singapore) and licensed to Tragara Pharmaceuticals (San Diego, CA, USA) in 2008. TG02 and TG101348 were synthesized by Sai Advantium Pharma (Hyderabad, India). SNS-032 was synthesized by S*BIO. Sunitinib and seliciclib were obtained from Sequoia Research Products (Pangbourne, UK) and LC Laboratories (Woburn, MA, USA), respectively.
In vitro kinase assays
These assays were performed at various contract research organizations indicated in Table 1 . Detailed protocols are available from CROs on request. ATP was used at or close to Km values.
Cell lines
The transformed murine pre-B cell lines Ba/F3-JAK2 V617F and Ba/F3-JAK2
WT were generous gifts of Dr Martin Sattler (Dana-Farber Cancer Institute, Boston, MA, USA). All cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA) with the exception of SET-2, Karpas 1106P and 32D, which were purchased from DSMZ (Braunschweig, Germany). NF114, a normal human dermal fibroblast, was obtained from CellResearchCorp., Singapore. Cell lines were cultured according to vendor's instructions using One Shot fetal bovine serum from Invitrogen (Carlsbad, CA, USA).
Primary AML blast cells
Primary cellsFeither peripheral blood mononuclear cells or bone marrow mononuclear cells from AML patientsFwere obtained from AllCells (Emeryville, CA, USA) and ProteoGenex (Culver City, CA, USA). Cells were thawed in the AML blast expansion medium (StemSpan Serum-Free Expansion Medium from StemCell Technologies, Vancouver, BC, Canada) containing 100 ng/ml of FLT3 ligand, 100 ng/ml of stem cell factor, 20 ng/ml of interleukin-3 and 20 ng/ml of interleukin-6 and plated at 2.5 Â 10 5 cells/ml. The cytokines were diluted 100-fold from the cytokine cocktail CC100 (StemCell Technologies). Cells were diluted every 2-4 days to a density of 3 Â 10 5 per ml. Between day 10 and 13, the expanded blasts were counted on Beckman Coulter Z1Particle Counter (Brea, CA, USA) and aliquoted as follows: B1 Â 10 5 cells for FLT3 genotyping, B5 Â 10 5 cells for FACS analysis and B3 Â 10 6 cells for proliferation assay.
Animal models
Female BALB/c mice and female athymic BALB/c nude mice (BALB/cOlaHsd-Foxn1 nu ) were obtained from the Biological Resource Centre (BRC, Biopolis, Singapore) and female NOD/ SCID mice (NOD.CB17-Prkdc scid /ARC). from the Animal Resource Centre (ARC, Murdoch, WA, Australia) and were 9-16 weeks of age at the time of tumor implantation. Standard protocols were followed, in compliance with the National Institutes of Health and National Advisory Committee for Laboratory Animal Research guidelines (IACUC approval #0800371). Female BALB/c nude mice were implanted subcutaneously in the right flank with 1 Â 10 7 MV4-11 cells. Cells were resuspended in 50 ml serum-free growth medium, mixed 1:1 with Matrigel (Cat #354248; BD Biosciences, San Diego, CA, USA) and injected in a total volume of 100 ml. Tumor growth was monitored twice weekly. For the efficacy study, animals were randomised on day 11 after inoculation (day 0) into treatment groups with mean tumor volumes of 146-150 mm 3 . Mice were treated daily for 21 days with 10-40 mg/kg TG02 hydrochloride or vehicle (MC/Tween). For the second experiment, animals were treated with vehicle or 30 mg/kg TG02 citrate daily or 60 mg/kg TG02 citrate every fourth day. For the pharmacokinetic-pharmacodynamic study the average starting tumor volume was 328 mm 3 (range 144-550 mm 3 ). For the HL-60 intravenous model, 1 Â 10 7 HL-60 cells were injected in 0.2 ml serum-free medium into the tail vein of NOD/SCID mice. 15 days after cell inoculation, mice were randomized into 4 groups and drug treatment was initiated. Treatment was administered for 5 days followed by a 5-day break (5d on 5d off), for 3 cycles, using either 40 mg/kg per oral or 20 mg/kg intraperitoneal route. Mice were monitored for hind-leg paralysis and body weight changes daily. Mice that reached the end point (paralysis in all limbs, moribund state) were terminated. The Prism 5 Logrank test was used to determine the statistical significance of any difference in the survival curves between a treatment group and the corresponding vehicle group. All doses for in vivo experiments were given as free base equivalents.
Additional methods and reagents
The following methods and reagents are described in Supplementary Information: preparation of genomic DNA, genotyping for FLT3-ITD, detection of JAK2V617F mutation, pFLT3 ELISA, flow cytometry, pharmacokinetic analysis, cell proliferation assay, primary erythroid progenitor cells, western blot assays.
Results
TG02 demonstrates a novel kinase inhibitory spectrum
TG02, a novel pyrimidine-based macrocycle (Figure 1 ), was originally discovered as a potent inhibitor of CDK2, JAK2 and FLT3. Subsequently, it was tested against a panel of 63 kinases in in-vitro assays (Table 1) , covering all major sub-families of the human kinome. TG02 most potently inhibited CDK isoforms, with IC 50 of 3-9 nM for CDKs 1,2,3,5 and 9 and IC 50 of 37 nM for CDK7. CDK6 was inhibited somewhat less potently, with an IC 50 of 113 nM, and CDK4 was not significantly inhibited. TG02 TG02 has potent anti-proliferative effects in tumor cell lines as well as primary cells and induces cell cycle arrest and apoptosis
To assess the effects of combining multiple targets in one molecule, the anti-proliferative activity of TG02 was compared with SNS-032 (a CDK inhibitor without JAK2 activity Table 1 ). In the combined 18-tumor panel, the mean IC 50 for TG02 (0.19 mM) was significantly lower than that for SNS-032 (0.44 mM) (P ¼ 0.0094). TG02 showed a stronger inhibition of the liquid tumor panel (0.13 mM) compared with the solid tumor panel (0.30 mM), whereas SNS-032 had similar effects on both. Within the liquid tumor panel, there was no significant difference in sensitivity between JAK2/FLT3 wild type (first 4 lines) versus mutant or activated-WT bearing cell lines (last 8 lines) (P ¼ 0.7591). TG02 was almost always more potent than SNS-032 in all cell lines (lower IC 50 ), but the mean fold difference in IC 50 values was significantly larger for the JAK2-dependent panel (4.5) compared with the non-JAK2-dependent panel (1.5-fold for the first 6 lines in the liquid tumor panel, 1.7 for the solid tumor panel). This suggests that the additional JAK2 activity leads to enhanced cytotoxic activity of TG02 relative to SNS-032 in these JAK2-dependent lines. In the context of the JAK2-dependent panel, TG02 was also significantly more potent (0.14 mM) than the selective JAK2 inhibitor TG101348 (0.93 mM) (P ¼ 0.0028). TG02 inhibited the normal fibroblast in the same concentration range as the solid tumor cell lines, where potencies were lower than on the liquid tumor panel.
Next, the anti-proliferative activities of TG02 and reference compounds were tested in primary diseased cells. In ex vivo expanded erythroid progenitors from polycythemia vera patients (n ¼ 14), TG02 significantly compromised the viability of these cells (0.047 mM) more potently than either SNS-032 (0.12 mM) or TG101348 (0.20 mM) (Figure 2b , Supplementary Table 2A ). All three drugs exhibited equivalent cytotoxic effects on erythroid progenitors expanded from healthy volunteers (Supplementary Table 2B ).
In expanded blast cells from AML patients (n ¼ 16, Figure 2c , Supplementary Table 3), TG02 was compared with 2 CDK inhibitors (SNS-032, seliciclib 11 ) and a FLT3 inhibitor (sunitinib 13 ). Five of the expanded blast cell samples were randomly selected for FACS analysis, and 490% were found to express the IL-3 receptor alpha chain CD123, a marker for human AML stem cells, 14 demonstrating that they were the intended population (data not shown). The mean IC 50 obtained was 60 nM for TG02, 184 nM for SNS-032 and 45.6 mM for seliciclib. The number of FLT3-ITD samples was too small to make a statistically significant comparison between WT and mutated patients. Sunitinib, a FLT3 inhibitor without CDK activity, was less potent than TG02, with a mean IC 50 of 4 mM. The antiproliferative action of TG02 was consistent with the observation of G1 cell cycle arrest in treated MV4-11 cells (Figure 3a Supplementary Table 1 ) was determined using the CellTiter 96 Aqueous One Solution MTS assay. Cells were seeded in log-growth phase, treated with serial dilutions of the drug in triplicates, the assay reagents were added after 48 h incubation and the IC 50 values determined using XLfit software. The assay was repeated at least three times for each cell line. Values shown are mean IC 50 . The JAK2 inhibitor TG101348 was only tested against the 6 cell lines where JAK2 is implicated in proliferation. (b) Erythroid progenitors were expanded from peripheral blood mononuclear cells of 14 polycythemia vera patients (see Supplementary Table 2 ). The cells were grown independently in two separate experiments (triplicates for each dose). IC 50 for TG02 are compared with those for the CDK inhibitors SNS-032 and the JAK2 inhibitor TG101348. (c) AML blasts were expanded from either peripheral blood mononuclear cells or bone marrow of 16 AML patients (see Supplementary Table 3 ). The cells were grown independently in two separate experiments (triplicates for each dose). IC 50 for TG02 are compared with those for the CDK inhibitors SNS-032 and seliciclib, and the FLT3, VEGFR and pan-kinase inhibitor sunitinib.
TG02, a multi-kinase anti-leukemic agent KC Goh et al with more consistent anti-proliferative and pro-apoptotic activity than other compounds inhibiting subsets of these targets (CDKs, JAK2, FLT3). Table 4) . At the higher concentrations of both compounds, cells were undergoing apoptosis, resulting in less detectable actin (beyond 0.8 and 80 mM, respectively). The IC 50 of TG02 against pFLT3 in cells (3 h treatment) was 4,700 nM and 59 nM for sunitinib (Figure 4b, Supplementary Table 4 ). In the FLT3-ITDdependent cell lines such as MV4-11, STAT5 has been described to be directly downstream of the FLT3-ITD mutant and independent of JAK activity. 15 The mean IC 50 of TG02 for pSTAT5 was 560 nM and 50 nM for sunitinib. It is not known why the IC 50 values for pFLT3 versus pSTAT5 inhibition are consistent for sunitinib, but 48-fold different for TG02. A possible explanation is that TG02 is inhibiting other kinase(s) that phosphorylate STAT5. In summary, TG02 appeared to directly inhibit CDK2 more potently than FLT3 in MV4-11 cells.
TG02 potently inhibits CDK activity in cells
The effects on JAK-STAT signaling were studied in Karpas 1106P (hyper-activated wild-type JAK2) 16 and SET-2 cells (constitutively phosphorylated JAK2 V617F ) 17 and compared with TG101348. In Karpas 1106P, the IC 50 for pJAK2 (Y1007/8) and pSTAT3 inhibition by TG02 was 63 and 53 nM, respectively, compared with 150 and 90 nM for TG101348 (Figure 4c 
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Supplementary Table 4 ). Overall these data show that TG02 effectively blocks intracellular phosphorylation of substrates for CDK2, JAK2 and FLT3 at sub-micromolar concentrations.
TG02 induces markers of G1 arrest and apoptosis
To further analyze functional changes in cells, HL-60 cells were treated with TG02 for 3 h. TG02 blocked mRNA transcription as demonstrated by a dose-dependent decrease in the phosphorylation of RNA polymerase II Ser2 (Figure 5a , top panel). Whereas SNS-032 inhibited phosphorylation of RNA pol II Ser2 at 300 nM, TG02 had a marked effect at concentrations as low as 30 nM, indicating that CDK9 is the most sensitive target of the drug as reflected by Table 1 . TG02 also led to dose-dependent decrease in cdc6 levels ( Figure 5a , 2nd panel from top), a protein that is stabilized through phosphorylation by CDK2. 20 Cyclin E, a cyclin partner of CDK2 that is degraded on S-phase entry, showed increased levels after treatment with 0.3-3 mM TG02 (Figure 5a , 3rd panel from top), supporting the G1 arrest shown in Figure 3a . Levels of the anti-apoptotic Mcl-1 were downregulated whereas levels of the pro-apoptotic Bcl-2 remained unchanged in TG02-treated samples. Cell death was induced by TG02 at concentrations X300 nM as indicated by an increase in cleaved poly (ADP ribose) polymerase (PARP, Figure 5a , 2nd panel from the bottom). Changes in RNA pol II Ser2, Mcl-1 and cleaved PARP were time-dependent in HL-60 cells (Figure 5b ). In summary, these data show that TG02 exposure leads to CDK9 inhibition, followed by G1 phase arrest and apoptotic induction.
TG02 is enriched in tumor tissues and shows effective target engagement
The pharmacokinetics (PK) of TG02 was determined in MV4-11 tumor-bearing nude mice after a single oral dose of 30 or 60 mg/kg (Figures 6a and b, Supplementary Table 5 ). Maximal plasma concentrations (C max ) were 74 and 154 ng/ml for 30 and 60 mg/kg, respectively, measured at 0.5 h post-dose (T max ). At 60 mg/kg dosing, the mean plasma concentration of TG02 remained above cellular IC 50 in MV4-11 for B8 h. Drug levels in the tumors remained above the IC 50 for MV4-11 cells for 8 and 24 h for the low and high dose groups, respectively. Figures 6a and b showed that TG02 was selectively retained at supra-therapeutic levels in tumor tissues. To assess target engagement by TG02 in tumor tissue, MV4-11 tumor lysates were analyzed after tumor-bearing mice were treated with a single dose of 60 mg/kg. Levels of phospho-RNA poly II Ser2 were used as a read-out for CDK9 inhibition. Inhibition was observed from 0.5 h, reached a maximum (100%) at 6 h and showed total recovery by 24 h (Figure 6c, top panel) . The pRb signal, read-out for CDK2, was inhibited by B30% after 0.5 h, reduced by 490% between 6-24 h and returned to pre-treatment levels after 48 h (Figure 6c, second from top) . Levels of pSTAT5 (Y694) were assessed as a read-out for FLT3 inhibition. Maximum inhibition was observed at 3-6 h, but the signal recovered beyond vehicle baseline at 16-24 h. In a separate experiment, the effects of a single acute dose of TG02 citrate (30, 40 or 60 mg/kg) on pFLT3 (Y591) levels in the tumor lysates was assessed by ELISA. All three dose levels showed effective reduction in pFLT3, with maximum reductions (12 h post-dose) of 23.5, 51.5 and 65% from baseline levels shown in animals treated with 30, 40 and 60 mg/kg, respectively (Figure 6d) . Apoptosis, as exemplified by the increased levels of cleaved PARP (Figure 6c second from the bottom), occurred between 6 and 24 h. Taken together, these data show that TG02 effectively inhibits CDK2, CDK9 and FLT3 in vivo, causing apoptosis in the tumor tissues.
TG02 is efficacious in animal models of AML
The efficacy of TG02 was initially tested in a subcutaneous (s.c.) AML model (MV4-11). The average tumor volume at start was 87 mm The experiment was performed as described under A, except that n ¼ 12/group and TG02 citrate salt was used.
TG02, a multi-kinase anti-leukemic agent KC Goh et al tolerated with no body weight loss at termination (Supplementary Table 6 ). Tumors had regressed completely in 4/10, 2/10 and 8/9 mice for the 10, 20 and 40 mg/kg groups, respectively. In a second AML model (HL-60 intravenous), vehicle-treated NOD/SCID mice developed bilateral hind leg paralysis, a hallmark symptom of this disease model, between days 29 and 41, which was accompanied by progressive body weight loss due to disease. The median survival of the animals of the 3 vehicle groups was between 39-42 days. All mice in the vehicle groups reached the endpoint (as described in Materials and methods) at the latest by day 53. Mice treated, using a 40 mg/kg per oral 5d on 5d off Â 3-cycle regimen, had a median survival of 48 days, which translated to a 9-day protection compared with the corresponding vehicle group (p o0.001). Mice treated with 100 mg/kg per oral 2d on 5d off Â 4-cycle regimen had a median survival of 59 days, increasing their median survival by 19 days compared with the corresponding vehicle group (Po0.001). Mice treated with a 20 mg/kg intraperitoneal 5d on 5d off Â 3-cycle regimen showed the best efficacy with a median survival of 68 days, amounting to a 26-day protection (Po0.0001) (Figure 7b ). Notably, 4/9 mice in this group did not develop hind-leg paralysis at all during the study. Taken together, these data demonstrated the efficacy of TG02 in two different models of AML.
As the citrate salt of TG02 was chosen as the preferred form for further development studies, the MV4-11 s.c. efficacy model was repeated with citrate salt to investigate new dosing regimens. In this second study, treatment was initiated when tumors were larger than in the first study (average size of 147 mm 3 ). Mice were treated with either 30 mg/kg daily or 60 mg/kg TG02 every fourth day (Q4D) Â 6 days, starting on day 0. The tumor growth inhibition achieved on day 21 was 86% for both schedules (Po0.01) (Figure 7c ). The average tumor weight in the treated groups was significantly (Po0.001) reduced by 75 and 84% compared with vehicle-treated animals for the 30 and 60 mg/kg groups, respectively (data not shown). Both schedules were well tolerated with no BW loss at the end of study (Supplementary Table 6 ). The two dosing schedules were not significantly different in their efficacy on either tumor volume or weight.
Discussion
Advanced hematologic malignancies, including AML, constitute an area with unmet medical need, and recent advances in the understanding of their molecular etiologies engendered hopes of targeted therapies. 21 Among the genetic aberrations identified in hematologic malignancies are FLT3, JAK2 and the CDKs. The specific indications that may be suitable for these targets include (a) chronic lymphocytic leukemia, multiple myeloma and mantle cell lymphoma, where CDK inhibitors have shown preliminary clinical efficacy; (b) acute myeloid leukemia, where the FLT3-ITD mutation is present in B30% of the patients 9 and activated JAK2 is an emerging target in both circulating blasts and tumor stem cells; 22, 23 and (c) myeloproliferative diseases where JAK2 lesions were identified in 450% of the patients. 24 In this study, we present the preclinical evaluation of a novel chemical entity, TG02, a small molecule that inhibits these oncogenic kinases.
TG02 is a broad-spectrum CDK inhibitor, with inhibitory activity against CDK1, 2, 7 and 9. This spectrum is noteworthy because the combined inhibition of transcriptional CDKs with cell-cycle regulatory CDKs has been shown to be advantageous for effective apoptotic induction in tumor cells. 25 Within the Janus kinase family, in vitro kinase data show TG02 to be most potent against JAK2 and TYK2. Importantly, TG02 demonstrated B240-fold selectivity for JAK2 relative to JAK3. As JAK3 deficiency has been shown to lead to severe immune disorders in humans, 26 it is desirable to avoid inhibiting this JAK isoform. The interesting CDK-JAK2-FLT3 inhibitory profile of TG02 suggests therapeutic potential for treating a broad range of hematological malignancies. The other kinase targets of TG02 (Table 1) , including ERK5, TYRO3 and p38d, may further broaden therapeutic indications to a wide range of solid tumors, if they are confirmed in a cellular and functional context. TG02 demonstrated effective inhibition of CDK and JAK2 signaling pathways in the relevant cell models examined. It was much more potent than seliciclib in inhibiting phosphorylation of Rb protein. In wild-type JAK2-bearing Karpas 1106P cells, both pJAK2 and pSTAT3 were strongly inhibited. In the JAK2 V617F -bearing cell line SET2, pSTAT3 was dose-dependently inhibited, although pJAK2(Y1007/1008) levels were increased. Based on molecular modeling, we speculate that TG02 preferentially binds to and stabilizes a 'pre-activated' form of JAK2 V617F , already phosphorylated at Y1007/8, leading to an accumulation of this phosphorylated JAK2
V617F species. Such a scenario is similar to what others have proposed after independent observations with structurally unrelated JAK2 inhibitors in other JAK2
V617F -bearing cell lines. 18, 19 In MV4-11 cells, TG02 showed inhibition of pFLT3 and pSTAT5, but at a higher concentration than sunitinib, consistent with the in vitro potencies of these 2 compounds. However, the much higher IC 50 for pFLT3 inhibition (4.7 mM) compared with the cytotoxic dose (0.16 mM) poses the question of the extent to which FLT3 impacts proliferation relative to CDK.
In HL-60 cells, the blockade in signaling pathways translated into downstream processes that reflected transcriptional inhibition (decrease in phosphorylation of RNA pol II Ser2), failure of S-phase entry (cyclin E accumulation) and apoptotic induction (depletion of Mcl-1, and cleavage of PARP). Inhibition of the oncogenic signaling pathways by TG02 resulted in functional consequences for the treated cells. Dose-and time-dependent apoptotic induction, probably due to depletion of the short-lived anti-apoptotic protein Mcl-1 as a result of the transient transcriptional block caused by inhibition of CDK9, and cell cycle arrest were observed in MV4-11 and HL-60 cells. Taken together, these data demonstrated that TG02 exerted potent inhibition on its main target kinases to induce cell cycle arrest and cell death.
Importantly, comparison of TG02 with reference inhibitors that block only one of the kinase targets (CDK only or JAK2 only) demonstrated the significant benefit of combined CDK and JAK2 targeting. In both JAK2-dependent tumor cell lines and erythroid progenitors from polycythemia vera patients, our data revealed the higher efficacy of TG02 compared with SNS-032 and TG101348, attesting to the advantage of co-targeting CDKs and additional kinases. We attribute the equivalent cytotoxicity against normal erythroid progenitors to the presence of erythropoietin in the expansion medium, contributing to the JAK2 dependence of expanded cells. SB1518, a JAK2 inhibitor, that also showed equipotent cytotoxic effects on expanded progenitors from healthy or polycythemia vera subjects, can be administered to patients with a good therapeutic window. 27 The clinical testing of TG02 is still underway to determine whether a therapeutic window can be achieved in leukemic patients.
Additionally, TG02 was superior to both SNS-032 and the FLT3 inhibitor sunitinib against primary blasts from AML patients. This approach has the effect of delivering a combination therapy in a single molecule and is a promising drug discovery platform for the future.
TG02, a multi-kinase anti-leukemic agent KC Goh et al TG02 demonstrated favorable oral pharmacokinetic properties in mouse tumor models. It was retained in tumor masses at supra-therapeutic levels for 8-24 h, depending on the dose. Consequently, pathway biomarkers were suppressed for sustained periods after dosing. These translated to anti-tumor efficacy and survival benefits in both FLT3-dependent (MV4-11) and independent (HL-60) models of AML, using either daily or intermittent regimen.
In summary, TG02 is a novel chemical entity with broadspectrum activity against oncogenic CDKs, with the additional benefit of targeting JAK2 and FLT3, the two kinases that are key to the etiology of several hematopoietic malignancies. Compared with mono-targeted reference inhibitors, TG02 is more consistently anti-proliferative across tumor cell lines as well as primary diseased cells. TG02's unique kinase spectrum and favorable pharmacological profile provide the rationale for its current evaluation in patients with advanced leukemias.
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